Kura Oncology, Inc. (KURA)

Kura Oncology's stock has been influenced by several events, including the FDA approval of Komzifti in November 2025 and a global collaboration with Kyowa Kirin in November 2024. Kura received two $30 million milestone payments in October and November 2025 related to the first patient dosing in the pivotal KOMET-017 clinical trial. The company missed GAAP revenue estimates in Q2 2025 and Q3 2025, despite collaboration revenue from Kyowa Kirin. As of February 5, 2026, the stock closed at $7.40, with a one-year change of -14.45%. On February 2, 2026, Kura Oncology awarded nonstatutory stock options to new hires.

Traditional demand seasonality is not a primary factor for Kura Oncology, as demand for cancer treatments is driven by disease incidence and medical need. Any seasonality would more likely relate to clinical trial readouts, regulatory milestones, or broader market trends affecting the biotechnology sector, rather than a cyclical demand for its specific cancer therapies.

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on personalized therapeutics for solid tumors and blood cancers, operating within the Biotechnology industry. The company develops small molecule drug candidates targeting cell signaling pathways critical for cancer progression, using molecular diagnostics to identify patients likely to benefit from their therapies. Key products include KOMZIFTI (ziftomenib), an FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated AML, currently in Phase 3 trials for frontline AML. Tipifarnib, a farnesyl transferase inhibitor, has been investigated for various cancers. Darlifarnib (KO-2806), a next-generation FTI, is in Phase I trials for solid tumors.

Kura Oncology is headquartered in San Diego, California. The company plans U.S. commercialization for Komzifti (ziftomenib) and has a global partnership with Kyowa Kirin Co., Ltd. for ex-U.S. development and commercialization.

Kura Oncology's brand reputation has been positively impacted by the FDA approval of KOMZIFTI (ziftomenib) and the strategic collaboration with Kyowa Kirin Co., Ltd. The FDA approval establishes the company as a leader in menin inhibitors and validates its precision oncology approach. The company's mission to advance precision medicines and improve patient outcomes also enhances its brand image.

Kura Oncology has significant institutional ownership, with 323 institutional owners and shareholders holding 90,858,641 shares, representing approximately 73.8% of outstanding shares. Individual insiders hold about 6.40%. Major institutional owners include BlackRock, Inc., BVF Inc/il, Suvretta Capital Management, Llc, and Vanguard Group Inc.